The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

CHEMBL341138     6-ethyl-2-sulfanylidene-5- tetradecyl-1H...

Synonyms: LS-136011, AC1O44I4
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Compound 1

  • Mechanistically, compound 1 prevents bone loss in vivo by inhibiting osteoclast-mediated bone resorption, ultimately preventing cancellous bone turnover [1].
  • C1 treatment inhibited C. trachomatis but not T4SS-expressing Coxiella burnetii development in a dose-dependent manner [2].
  • We therefore employed the small molecule Yersinia T3SS inhibitor N'-(3,5-dibromo-2-hydroxybenzylidene)-4-nitrobenzohydrazide, designated compound 1 (C1), to examine the interdependence of the chlamydial T3SS and development [2].
  • When dosed orally at 30 mg/kg twice a day (b.i.d.) in the chronic ovariectomy (OVX)-induced rat model of osteopenia, compound 1 also prevented bone loss [1].
  • In MT-4 cells, compound 1 inhibits HIV-1 with an ED50 of 1.3 microM [3].

Psychiatry related information on Compound 1


High impact information on Compound 1

  • High concentrations of either compound (1) drastically reduced the number of primary HPP-CFC colonies and totally abolished their recloning capacity and (2) inhibited HSC proliferation [7].
  • Furthermore, the compounds that contained only a stem peptide (pentapeptide, compound 1) and (DAP-PP, compound 2) as well as muramyldipeptide (compound 3) exhibited no binding indicating that the muramyltripeptide (compound 4) is the smallest peptidoglycan fragment that can be recognized by PGRP-Ialpha [8].
  • Compound 1 reduced viral RNA in replicon cells with an IC(50) of approximately 0.5 microm, suggesting that the inhibitor was able to access the perinuclear membrane and inhibit the polymerase activity in the context of a replicase complex [9].
  • Compound 1 is a potent inhibitor of both soluble and membrane-associated isoforms of native PKG, as well as recombinant enzyme, with an IC(50) of <1 nm [10].
  • Fatty acyl-CoA oxidase (FACO) activity and mRNA were increased after treatment with either fenofibric acid or compound 1 in rat hepatocytes [11].

Chemical compound and disease context of Compound 1


Biological context of Compound 1

  • When assaying the human recombinant cPLA2 using membranes isolated from [3H]arachidonate-labeled U937 cells as substrate, 2-(2'-benzyl-4-chlorophenoxy)ethyl-dimethyl-n-octadecyl-ammonium chloride (compound 1) was found to inhibit the enzyme in a dose-dependent manner (IC50 = 5 microM) [17].
  • Hence, inhibition of cholesterol esterase-catalyzed hydrolysis of p-nitrophenyl butyrate by compound 1 or 2 in the aqueous or micellar phase occurs via a carbamyl-cholesterol esterase mechanism [18].
  • Thus, compound 1 represents a novel structural class of inhibitor of cPLA2 that partitions into the phospholipid bilayer and competes with the phospholipid substrate for the active site [17].
  • The inhibition of cholesterol esterase by compound 1 or 2 shows saturation kinetics with increasing inhibitor concentration [18].
  • Furthermore, in the absence of an in vitro-reconstituted HCV replicase assay employing viral and host proteins, the ability of compound 1 to inhibit NS5B-directed viral RNA replication was determined using the Huh7 cell-based HCV replicon system [9].

Anatomical context of Compound 1

  • This discrepancy was reconciled by showing that these shorter-chained analogs did not partition into the [3H]arachidonate-labeled U937 membranes as effectively as compound 1 [17].
  • Compound 1 also potently inhibited an ER-, HER-2 overexpressing breast cancer cell line [19].
  • We previously reported compound 1 as a potent farnesyl protein transferase (FPT) inhibitor that exhibited reasonable pharmacokinetic stability and showed moderate in vivo activity against a variety of tumor cell lines [20].
  • A HeLa cell model that mimics in vivo conditions showed that compound 1 chemically attenuates the pathogen to the advantage of the eukaryotic cell [21].
  • Compound 4 is about fourfold less potent than compound 1 as an antiviral agent but is about 40-fold less toxic to the host Vero cells [22].

Associations of Compound 1 with other chemical compounds

  • First-order decreases in cholesterol esterase activity effected by compound 1 or 2 are also observed in the presence of taurocholate/phosphatidylcholine micelles [18].
  • In this study five derivatives of compound 1 (compounds 2-6) were selected because of their sensitivity in facilitating complex formation between the 1alpha,25(OH)(2)D(3) receptor (VDR) and the retinoid X receptor on a 1alpha,25(OH)(2)D(3) response element that was comparable to that of the natural hormone (0.2-0.9 nM) [23].
  • After further pharmacological and toxicological evaluation as well as physical properties, the hydrochloride 2 (JTV-605) of compound 1 was selected for clinical studies as a potent AVP antagonist with a long duration of action [24].
  • We examined interactions with purified tubulin of synthetic sarcodictyins A and B and eleutherobin (coral-derived antimitotic agents) and of compound 1, an analogue of sarcodictyin A methylated at the C-3 oxygen atom (i.e., the methyl ketal analogue of sarcodictyin A and thus structurally similar to eleutherobin but lacking the C-3 sugar moiety) [25].
  • The inhibitory activities of both compounds on HCMV propagation in vitro were similar against the AD 169 and Towne strains, with 50% inhibitory concentrations ranging from 0.02 to 0.17 microgram/ml for cidofovir and < 0.05 to 0.09 microgram/ml for compound 1 [13].

Gene context of Compound 1

  • Compound 1 inhibited MIP-1alpha- and RANTES-induced migration in peripheral blood mononuclear cells in a dose-responsive manner [26].
  • Compound 1, which displayed modest potency and selectivity for ERbeta vs ERalpha, was identified via high-throughput screening utilizing an ERbeta SPA-based binding assay [27].
  • To elucidate its structure-function-activity relationship, we synthesized nine different analogues of ethyl 3',4',5'-trimethoxycinnamate, i.e., compounds 3-11, and compared the ICAM-1 inhibitory activity of compound 1 with those of its synthetic analogues as well as the corresponding acids 12-15 [28].
  • However, using a commercial RIA and immunoblots, we showed that PRL levels increase significantly in response to treatment with the ER-alpha selective agonist, compound 1 [29].
  • In this article, we report the synthesis, in vitro characterization, pharmacokinetics, and pharmacodynamics of an orally bioavailable, potent, small molecule GnRH receptor antagonist N-{4,6-dimethoxy-2-[(3-morpholin-4-ylpropyl)amino]pyrimidin-5-yl}-5-[3,3,6-trimthyl-2,3-dihydro-1H-inden-5-yl)oxy]-2-furamide (compound 1) [30].

Analytical, diagnostic and therapeutic context of Compound 1

  • In addition, blood samples from 28 normal subjects, 28 cancer patients with different malignancies, and 39 patients with a variety of other than cancer ailments were screened for compound 1 on a blind basis using reverse phase ion-paired high-performance liquid chromatography [31].
  • Unlike 7b and 36c, compound 1 and related 2,4,6-trimethoxyanilides (13j, 30c,d) showed poor oral activity in the rabbit bioassay [32].
  • The pharmacokinetic profile of compound 1 after oral administration revealed that maximal plasma levels of compound were reached within 1 h and the half-life of the compound to be approximately 2 h in rats [33].
  • In 72-hr UW-preserved kidneys, the microvessels of both cortex and medulla were completely visualized with silicon rubber compound 1 hr after reperfusion [34].
  • Compound 1 possessed a straight channel, with an opening of approximately 0.5x0.8 nm, which contained the water of crystallization [35].


  1. Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat. Lark, M.W., Stroup, G.B., Dodds, R.A., Kapadia, R., Hoffman, S.J., Hwang, S.M., James, I.E., Lechowska, B., Liang, X., Rieman, D.J., Salyers, K.L., Ward, K., Smith, B.R., Miller, W.H., Huffman, W.F., Gowen, M. J. Bone Miner. Res. (2001) [Pubmed]
  2. Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle. Wolf, K., Betts, H.J., Chellas-Géry, B., Hower, S., Linton, C.N., Fields, K.A. Mol. Microbiol. (2006) [Pubmed]
  3. Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs. Bell, F.W., Cantrell, A.S., Högberg, M., Jaskunas, S.R., Johansson, N.G., Jordan, C.L., Kinnick, M.D., Lind, P., Morin, J.M., Noréen, R. J. Med. Chem. (1995) [Pubmed]
  4. Extending the Time: Solvothermal Syntheses, Crystal Structures, and Properties of Two Non-isostructural Thioantimonates with the Composition [Mn(tren)]Sb(2)S(4). Schaefer, M., Kurowski, D., Pfitzner, A., Näther, C., Rejai, Z., Möller, K., Ziegler, N., Bensch, W. Inorganic chemistry. (2006) [Pubmed]
  5. Juliflorine: a potent natural peripheral anionic-site-binding inhibitor of acetylcholinesterase with calcium-channel blocking potential, a leading candidate for Alzheimer's disease therapy. Choudhary, M.I., Nawaz, S.A., Zaheer-ul-Haq, n.u.l.l., Azim, M.K., Ghayur, M.N., Lodhi, M.A., Jalil, S., Khalid, A., Ahmed, A., Rode, B.M., Atta-ur-Rahman, n.u.l.l., Gilani, A.U., Ahmad, V.U. Biochem. Biophys. Res. Commun. (2005) [Pubmed]
  6. Preparation and pharmacological evaluation of N3-substituted thymidine derivatives as central depressants. Kimura, T., Watanabe, K., Tateoka, Y., Kondo, S., Ho, I.K., Yamamoto, I. Chem. Pharm. Bull. (1993) [Pubmed]
  7. Dual action of retinoic acid on human embryonic/fetal hematopoiesis: blockade of primitive progenitor proliferation and shift from multipotent/erythroid/monocytic to granulocytic differentiation program. Tocci, A., Parolini, I., Gabbianelli, M., Testa, U., Luchetti, L., Samoggia, P., Masella, B., Russo, G., Valtieri, M., Peschle, C. Blood (1996) [Pubmed]
  8. Selective recognition of synthetic lysine and meso-diaminopimelic acid-type peptidoglycan fragments by human peptidoglycan recognition proteins I{alpha} and S. Kumar, S., Roychowdhury, A., Ember, B., Wang, Q., Guan, R., Mariuzza, R.A., Boons, G.J. J. Biol. Chem. (2005) [Pubmed]
  9. Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. Dhanak, D., Duffy, K.J., Johnston, V.K., Lin-Goerke, J., Darcy, M., Shaw, A.N., Gu, B., Silverman, C., Gates, A.T., Nonnemacher, M.R., Earnshaw, D.L., Casper, D.J., Kaura, A., Baker, A., Greenwood, C., Gutshall, L.L., Maley, D., DelVecchio, A., Macarron, R., Hofmann, G.A., Alnoah, Z., Cheng, H.Y., Chan, G., Khandekar, S., Keenan, R.M., Sarisky, R.T. J. Biol. Chem. (2002) [Pubmed]
  10. Purification and molecular characterization of cGMP-dependent protein kinase from Apicomplexan parasites. A novel chemotherapeutic target. Gurnett, A.M., Liberator, P.A., Dulski, P.M., Salowe, S.P., Donald, R.G., Anderson, J.W., Wiltsie, J., Diaz, C.A., Harris, G., Chang, B., Darkin-Rattray, S.J., Nare, B., Crumley, T., Blum, P.S., Misura, A.S., Tamas, T., Sardana, M.K., Yuan, J., Biftu, T., Schmatz, D.M. J. Biol. Chem. (2002) [Pubmed]
  11. Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expresson. Lawrence, J.W., Li, Y., Chen, S., DeLuca, J.G., Berger, J.P., Umbenhauer, D.R., Moller, D.E., Zhou, G. J. Biol. Chem. (2001) [Pubmed]
  12. Discovery of antiglioma activity of biaryl 1,2,3,4-tetrahydroisoquinoline derivatives and conformationally flexible analogues. Mohler, M.L., Kang, G.S., Hong, S.S., Patil, R., Kirichenko, O.V., Li, W., Rakov, I.M., Geisert, E.E., Miller, D.D. J. Med. Chem. (2006) [Pubmed]
  13. Comparative study of the anti-human cytomegalovirus activities and toxicities of a tetrahydrofuran phosphonate analogue of guanosine and cidofovir. Bedard, J., May, S., Lis, M., Tryphonas, L., Drach, J., Huffman, J., Sidwell, R., Chan, L., Bowlin, T., Rando, R. Antimicrob. Agents Chemother. (1999) [Pubmed]
  14. Microbial glycosylation of erythromycin A. Kuo, M.S., Chirby, D.G., Argoudelis, A.D., Cialdella, J.I., Coats, J.H., Marshall, V.P. Antimicrob. Agents Chemother. (1989) [Pubmed]
  15. Synthesis of (E)-1-(5-chlorothien-2-yl)-2-(1H-imidazol-1-yl)ethanone 2,6-dichlorophenylhydrazone hydrochloride, a novel, orally active antifungal agent. Dyer, R.L., Ellames, G.J., Hamill, B.J., Manley, P.W., Pope, A.M. J. Med. Chem. (1983) [Pubmed]
  16. Anti-AIDS agents. 15. Synthesis and anti-HIV activity of dihydroseselins and related analogs. Huang, L., Kashiwada, Y., Cosentino, L.M., Fan, S., Chen, C.H., McPhail, A.T., Fujioka, T., Mihashi, K., Lee, K.H. J. Med. Chem. (1994) [Pubmed]
  17. Competitive, reversible inhibition of cytosolic phospholipase A2 at the lipid-water interface by choline derivatives that partially partition into the phospholipid bilayer. Burke, J.R., Witmer, M.R., Zusi, F.C., Gregor, K.R., Davern, L.B., Padmanabha, R., Swann, R.T., Smith, D., Tredup, J.A., Micanovic, R., Manly, S.P., Villafranca, J.J., Tramposch, K.M. J. Biol. Chem. (1999) [Pubmed]
  18. p-Nitrophenyl and cholesteryl-N-alkyl carbamates as inhibitors of cholesterol esterase. Hosie, L., Sutton, L.D., Quinn, D.M. J. Biol. Chem. (1987) [Pubmed]
  19. Antitumor Agents. 239. Isolation, structure elucidation, total synthesis, and anti-breast cancer activity of neo-tanshinlactone from Salvia miltiorrhiza. Wang, X., Bastow, K.F., Sun, C.M., Lin, Y.L., Yu, H.J., Don, M.J., Wu, T.S., Nakamura, S., Lee, K.H. J. Med. Chem. (2004) [Pubmed]
  20. Potent, selective, and orally bioavailable tricyclic pyridyl acetamide N-oxide inhibitors of farnesyl protein transferase with enhanced in vivo antitumor activity. Njoroge, F.G., Vibulbhan, B., Pinto, P., Bishop, W.R., Bryant, M.S., Nomeir, A.A., Lin, C., Liu, M., Doll, R.J., Girijavallabhan, V., Ganguly, A.K. J. Med. Chem. (1998) [Pubmed]
  21. Small-molecule inhibitors specifically targeting type III secretion. Nordfelth, R., Kauppi, A.M., Norberg, H.A., Wolf-Watz, H., Elofsson, M. Infect. Immun. (2005) [Pubmed]
  22. Synthesis and biological activities of 5-trifluoromethyl-5'-azido-2',5'-dideoxyuridine and 5-trifluoromethyl-5'-amino-2',5'-dideoxyuridine. Lin, T.S., Chai, C., Prusoff, W.H. J. Med. Chem. (1976) [Pubmed]
  23. Structure activity relationship of carboxylic ester antagonists of the vitamin D(3) receptor. Bury, Y., Steinmeyer, A., Carlberg, C. Mol. Pharmacol. (2000) [Pubmed]
  24. Synthesis and structure-activity relationships of 5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepine derivatives: novel arginine vasopressin antagonists. Cho, H., Murakami, K., Nakanishi, H., Fujisawa, A., Isoshima, H., Niwa, M., Hayakawa, K., Hase, Y., Uchida, I., Watanabe, H., Wakitani, K., Aisaka, K. J. Med. Chem. (2004) [Pubmed]
  25. The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site. Hamel, E., Sackett, D.L., Vourloumis, D., Nicolaou, K.C. Biochemistry (1999) [Pubmed]
  26. Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor. Hesselgesser, J., Ng, H.P., Liang, M., Zheng, W., May, K., Bauman, J.G., Monahan, S., Islam, I., Wei, G.P., Ghannam, A., Taub, D.D., Rosser, M., Snider, R.M., Morrissey, M.M., Perez, H.D., Horuk, R. J. Biol. Chem. (1998) [Pubmed]
  27. A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta. Henke, B.R., Consler, T.G., Go, N., Hale, R.L., Hohman, D.R., Jones, S.A., Lu, A.T., Moore, L.B., Moore, J.T., Orband-Miller, L.A., Robinett, R.G., Shearin, J., Spearing, P.K., Stewart, E.L., Turnbull, P.S., Weaver, S.L., Williams, S.P., Wisely, G.B., Lambert, M.H. J. Med. Chem. (2002) [Pubmed]
  28. Novel aromatic ester from Piper longum and its analogues inhibit expression of cell adhesion molecules on endothelial cells. Kumar, S., Arya, P., Mukherjee, C., Singh, B.K., Singh, N., Parmar, V.S., Prasad, A.K., Ghosh, B. Biochemistry (2005) [Pubmed]
  29. Biomarker discovery in rat plasma for estrogen receptor-alpha action. Holt, T.G., Flick, R.B., Rohde, E., Griffin, P., Rohrer, S.P. Electrophoresis (2005) [Pubmed]
  30. Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist. Li, H., Anderes, K.L., Kraynov, E.A., Luthin, D.R., Do, Q.Q., Hong, Y., Tompkins, E., Sun, E.T., Rajapakse, R., Pathak, V.P., Christie, L.C., Vazir, H., Castillo, R., Gregory, M.L., Castro, M., Nared-Hood, K., Paderes, G., Anderson, M.B. J. Med. Chem. (2006) [Pubmed]
  31. Vitamin B6 and cancer: synthesis and occurrence of adenosine-N6-diethylthioether-N-pyridoximine-5'-phosphate, a circulating human tumor marker. Tryfiates, G.P., Gannett, P.M., Bishop, R.E., Shastri, P.K., Ammons, J.R., Arbogast, J.G. Cancer Res. (1996) [Pubmed]
  32. Inhibitors of acyl-CoA:cholesterol O-acyltransferase. synthesis and pharmacological activity of (+/-)-2-dodecyl-alpha-phenyl-N-(2,4,6-trimethoxyphenyl)-2H-tetrazole-5- acetamide and structurally related tetrazole amide derivatives. O'Brien, P.M., Sliskovic, D.R., Picard, J.A., Lee, H.T., Purchase, C.F., Roth, B.D., White, A.D., Anderson, M., Mueller, S.B., Bocan, T., Bousley, R., Hamelehle, K.L., Homan, R., Lee, P., Krause, B.R., Reindel, J.F., Stanfield, R.L., Turluck, D. J. Med. Chem. (1996) [Pubmed]
  33. A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo. Arey, B.J., Seethala, R., Ma, Z., Fura, A., Morin, J., Swartz, J., Vyas, V., Yang, W., Dickson, J.K., Feyen, J.H. Endocrinology (2005) [Pubmed]
  34. The UW solution for canine kidney preservation. Its specific effect on renal hemodynamics and microvasculature. Ueda, Y., Todo, S., Imventarza, O., Furukawa, H., Oks, A., Wu, Y.M., Oguma, S., Starzl, T.E. Transplantation (1989) [Pubmed]
  35. Unique guest-inclusion properties of a breathing ionic crystal of K3[Cr3O(OOCH)6(H2O)3][alpha-SiW12O40].16 H2O. Uchida, S., Mizuno, N. Chemistry (Weinheim an der Bergstrasse, Germany) (2003) [Pubmed]
WikiGenes - Universities